Literature DB >> 25074524

Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future.

Victor Jiménez-Yuste1, Günter Auerswald2, Gary Benson3, Thierry Lambert4, Massimo Morfini5, Eduardo Remor6, Silva Zupančić Salek7.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25074524      PMCID： PMC4111811          DOI： 10.2450/2014.0298-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  31 in total

1.  Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

Authors:  I M Nilsson; E Berntorp; T Löfqvist; H Pettersson
Journal:  J Intern Med       Date:  1992-07       Impact factor: 8.989

2.  Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

Authors:  K Fischer; J Astermark; J G van der Bom; R Ljung; E Berntorp; D E Grobbee; H M van den Berg
Journal:  Haemophilia       Date:  2002-11       Impact factor: 4.287

Review 3.  Future of coagulation factor replacement therapy.

Authors:  F Peyvandi; I Garagiola; S Seregni
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

4.  Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.

Authors:  P W Collins; J Møss; K Knobe; A Groth; T Colberg; E Watson
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

5.  Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

Authors:  P W Collins; V S Blanchette; K Fischer; S Björkman; M Oh; S Fritsch; P Schroth; G Spotts; J Astermark; B Ewenstein
Journal:  J Thromb Haemost       Date:  2008-12-20       Impact factor: 5.824

6.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

7.  Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.

Authors:  J S Powell; D J Nugent; J A Harrison; A Soni; A Luk; H Stass; E Gorina
Journal:  J Thromb Haemost       Date:  2007-11-26       Impact factor: 5.824

8.  Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B.

Authors:  A Ahlberg
Journal:  Acta Orthop Scand Suppl       Date:  1965

9.  Thromboelastography in children with coagulation factor deficiencies.

Authors:  Meera Chitlur; Indira Warrier; Madhvi Rajpurkar; Wendy Hollon; Lolita Llanto; Carol Wiseman; Jeanne M Lusher
Journal:  Br J Haematol       Date:  2008-05-19       Impact factor: 6.998

10.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Authors:  Marilyn J Manco-Johnson; Thomas C Abshire; Amy D Shapiro; Brenda Riske; Michele R Hacker; Ray Kilcoyne; J David Ingram; Michael L Manco-Johnson; Sharon Funk; Linda Jacobson; Leonard A Valentino; W Keith Hoots; George R Buchanan; Donna DiMichele; Michael Recht; Deborah Brown; Cindy Leissinger; Shirley Bleak; Alan Cohen; Prasad Mathew; Alison Matsunaga; Desiree Medeiros; Diane Nugent; Gregory A Thomas; Alexis A Thompson; Kevin McRedmond; J Michael Soucie; Harlan Austin; Bruce L Evatt
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245
View more
  15 in total

Review 1.  Practical aspects of extended half-life products for the treatment of haemophilia.

Authors:  Thierry Lambert; Gary Benson; Gerry Dolan; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Silva Zupančić-Šalek; Elena Santagostino
Journal:  Ther Adv Hematol       Date:  2018-09-06

2.  Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Authors:  Brian Cooley; William Funkhouser; Dougald Monroe; Ashley Ezzell; David M Mann; Feng-Chang Lin; Paul E Monahan; Darrel W Stafford
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

3.  Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B.

Authors:  Maria Elisa Mancuso; Aaron Lubetsky; Brigitte Pan-Petesch; Toshko Lissitchkov; Azusa Nagao; Wilfried Seifert; Yanyan Li; Elena Santagostino
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

4.  The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B.

Authors:  J Michael Soucie; Paul E Monahan; Roshni Kulkarni; Barbara A Konkle; Marshall A Mazepa
Journal:  Blood Adv       Date:  2018-08-28

5.  Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.

Authors:  Robert Klamroth; Piotr Wojciechowski; Samuel Aballéa; Françoise Diamand; Zalmai Hakimi; Jameel Nazir; Lydia Abad-Franch; Stefan Lethagen; Elena Santagostino; Michael D Tarantino
Journal:  J Blood Med       Date:  2021-02-25

6.  Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.

Authors:  Pratima Chowdary; Manuel Carcao; Pål A Holme; Victor Jiménez-Yuste; Steven R Lentz; Judi Møss; Lone H Poulsen; Chunduo Shen; Alberto Tosetto; Allison Wheeler; Elena Santagostino
Journal:  Res Pract Thromb Haemost       Date:  2019-06-11

7.  Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).

Authors:  Nicola Curry; Canan Albayrak; Miguel Escobar; Pål Andre Holme; Susan Kearney; Robert Klamroth; Mudi Misgav; Claude Négrier; Allison Wheeler; Elena Santagostino; Midori Shima; Andrea Landorph; Sidsel Marie Tønder; Steven R Lentz
Journal:  Haemophilia       Date:  2019-02-28       Impact factor: 4.287

8.  Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.

Authors:  Beatrice Nolan; Anna Klukowska; Amy Shapiro; Antoine Rauch; Michael Recht; Margaret Ragni; Julie Curtin; Sriya Gunawardena; Sutirtha Mukhopadhyay; Deepthi Jayawardene; Bent Winding; Kathelijn Fischer; Raina Liesner
Journal:  Blood Adv       Date:  2021-07-13

9.  Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials.

Authors:  Jan Astermark; Piotr Wojciechowski; Samuel Aballéa; Zalmai Hakimi; Jameel Nazir; Robert Klamroth
Journal:  J Blood Med       Date:  2021-07-14

10.  Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP).

Authors:  Ola Sternebring; Charlotte Gabel-Jensen; Helene Jacobsen; Andrew James Benie; Inga Bjørnsdottir
Journal:  BioDrugs       Date:  2019-12       Impact factor: 5.807
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.